GlassScriptPhysician profile
Kathryn Gramlich
NPI 1710309588
$11,436.58
in general payments reported to CMS, 2019-2025
47 companies · $1,088 in 2025
The $1,088 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,700 · 2022: $2,791 · 2023: $2,689 · 2024: $2,168 · 2025: $1,088.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,945.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,945.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,614.96 | 2021-2025 | |
| Novo Nordisk INC | $1,499.96 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,009.98 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $848.54 | 2021-2024 | Farxiga, Breztri, Fasenra |
| Lilly USA, LLC | $788.08 | 2021-2025 | Mounjaro, Emgality, Jardiance |
| Novartis Pharmaceuticals Corporation | $758.30 | 2022-2025 | |
| Amgen INC. | $517.46 | 2021-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $456.74 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $384.27 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $379.57 | 2021-2024 | Jardiance |
| Axsome Therapeutics, INC. | $255.95 | 2023-2025 | Auvelity |
| Eisai INC. | $241.21 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $241.04 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $207.11 | 2022-2024 | Caplyta |
| Jazz Pharmaceuticals INC. | $185.05 | 2024-2025 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $184.45 | 2021-2025 | Austedo Xr, Austedo Xr, Airduo Digihaler |
| Merck Sharp & Dohme LLC | $177.97 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Neurocrine Biosciences, INC. | $135.43 | 2022-2024 | Ingrezza |
| Bayer Healthcare Pharmaceuticals INC. | $132.24 | 2023-2024 | |
| Lundbeck LLC | $125.48 | 2022-2024 | Vyepti |
| Exact Sciences Corporation | $123.27 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $107.89 | 2021-2023 | Veozah |
| Azurity Pharmaceuticals, INC. | $100.06 | 2023-2024 | Edarbi, Edarbi |
| Dexcom, INC. | $96.28 | 2022-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.44 | 2021-2023 | Xifaxan, Cycloset |
| Biohaven Pharmaceuticals, INC. | $80.80 | 2021 | |
| Verona Pharma, INC. | $79.07 | 2025 | Ohtuvayre |
| Biohaven Pharmaceutical Holding Company LTD. | $78.28 | 2022 | |
| Abbott Laboratories | $64.81 | 2023-2025 | Freestyle Libre 3 |
| Ironwood Pharmaceuticals, INC | $62.15 | 2022-2023 | Linzess |
| Upsher-Smith Laboratories LLC | $46.19 | 2021 | |
| Esperion Therapeutics, INC. | $45.72 | 2024-2025 | Nexletol |
| Ucb, INC. | $40.67 | 2023 | Briviact |
| Almatica Pharma LLC | $30.92 | 2023-2024 | Loreev Xr, Teriparatide |
| Phathom Pharmaceuticals, INC. | $29.72 | 2024-2025 | Voquezna |
| Antares Pharma, INC. | $28.94 | 2023 | Nocdurna, Xyosted, Tlando |
| Idorsia Pharmaceuticals US INC | $26.63 | 2022-2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $25.38 | 2021-2022 | |
| Amarin Pharma, INC. | $18.01 | 2021 | |
| Xeris Pharmaceuticals, INC. | $17.54 | 2025 | Keveyis |
| Medtronic, INC. | $17.49 | 2025 | Venaseal |
| Nestle Healthcare Nutrition INC. | $16.27 | 2023 | |
| Inari Medical, INC. | $16.10 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Janssen Pharmaceuticals, INC | $13.74 | 2023 | Spravato |
| Amneal Pharmaceuticals LLC | $13.62 | 2023 | Unithroid |
| Exeltis, USA INC. | $12.04 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Gramlich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.